Figure 2.
Efficacy of XF-73 dermal formulation (0.2% w/w) and mupirocin ointment (2%) in mice with experimental surgical wound infections caused by (A) S. aureus NRS384, (B) Low-level mupirocin-resistant strain S. aureus NRS384-MT-3, (C) High-level mupirocin-resistant strain S. aureus ATCC BAA-1708. Each datapoint corresponds to the log10 CFU/ wound tissue(g) measured. Data are presented as mean ± SD (n = 8 mice per treatment group).
